National Resource Center for Academic Detailing [NaRCAD]     857.307.3801
NaRCAD
  • About Us
    • Our Team
    • Contact Us
  • Learning Center
    • The AD Core Toolkit >
      • Opioid Safety Toolkit
      • HIV Prevention Toolkit
    • Examples of Program Materials
    • News & Media Center
  • The Detailing Directory
  • EVENTS
    • Training Series
    • CONFERENCE SERIES
    • THE CONFERENCE HUB
  • Blog
  • Partner Network
    • Partners by Location
  • About Us
    • Our Team
    • Contact Us
  • Learning Center
    • The AD Core Toolkit >
      • Opioid Safety Toolkit
      • HIV Prevention Toolkit
    • Examples of Program Materials
    • News & Media Center
  • The Detailing Directory
  • EVENTS
    • Training Series
    • CONFERENCE SERIES
    • THE CONFERENCE HUB
  • Blog
  • Partner Network
    • Partners by Location

The DETAILS BLOG

Capturing Stories from the Field: Reflections, Challenges, & Best Practices in Clinical Outreach Education

Curbing Informational Pollution

1/15/2016

1 Comment

 
Jerry Avorn, MD, Co-Director of NaRCAD, Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital
Picture
​Consider the following recent news development:
            A large multinational company is discovered to have purposely hidden the risks of one of its best-selling products by suppressing information about its adverse effects and presenting only a selective set of data about its impact, to cast it in a more favorable light than was accurate. The magnitude of this distortion was so great that it posed health risks for hundreds of thousands of people throughout the industrialized world.  The company admitted guilt and said it would try to do better in the future. No criminal charges were pressed, and none may ever be.
 
            I refer, of course, to Volkswagen. Last year, the carmaker was found to have rigged the pollution-control devices in its diesel cars to make it appear they were reducing emissions, but only when the car was being inspected. The rest of the time the autos spewed out pollutants far in excess of the allowed limits.  The engineers and executives who perpetrated this enormous hoax were not demons. They were employees of a large corporation who let the need for profit (or shareholder value, a more polite term) push them beyond the limits of accurately presenting data about their products. These things happen in large companies, including drugmakers, who have in the last decade or so had to pay over $15 billion in legal settlements, most of which dealt with such mis-statements of benefits and harms. Nothing personal; it’s just business.
 
            Anyone who is shocked about this should go back to review the imperatives of corporate life, as defined by the Nobel Prize-winning economist Milton Friedman. In a 1970 article, he noted that “There is one and only one social responsibility of business -- to use its resources and engage in activities designed to increase its profits….” Unfortunately, the second half of that sentence is often omitted: “…so long as it stays within the rules of the game, which is to say, engages in open and free competition without deception or fraud.” In an era of an overstretched and sometimes overmatched FDA, there’s a greater need than ever to present clinicians with an accurate depiction of the good and harm that medications can do.
 
            Of course, academic detailing is about far more than just correcting the excesses or misstatements of drugmakers. Our job is to present a comprehensive, un-skewed overview of the benefits and risks of medications and other health care decisions. But in doing so, we sometimes have to address misconceptions generated by some drugmakers who are, I suppose, just trying to give their shareholders a good return on their investment.  Whether a company makes cars or drugs, its staff at all levels are under tremendous pressure to increase sales.  This can often draw otherwise reasonable employees close to – or sometimes over – the line of what’s deceptive.
 
            In academic detailing, we don’t have to worry about sales goals or profit margins.  The only currency we need to maximize is accurate evidence; our only “shareholders” are patients and the clinicians who care for them. In a way, that’s the easiest and best part of our jobs.

1 Comment
Light info link
3/30/2016 10:23:50 am

Great post, Thank for share with us

Reply



Leave a Reply.

    Highlighting Best Practices

    We highlight what's working in clinical education through interviews, features, event recaps, and guest blogs, offering clinical educators the chance to share successes and lessons learned from around the country & beyond.

    Search Archives
    by Topic:

    All
    21st Century Cures Act
    5 Year Anniversary
    80% By 2018 Campaign
    Academic Detailing
    Addiction
    ADHD
    Affordable Care Act
    AHRQ
    AIDS
    Alaska
    Alosa Health
    Alternative Facts
    American Academy Of Pediatrics
    American Cancer Society
    Annual Community Survey
    Antibiotics
    Apply To Present
    Aspirin
    Atrius
    Autism
    Autism Screening
    Behavior Change
    Best Practices
    Big Data
    Blood Pressure
    Boston
    Breast Cancer
    California
    Cancer Roundtable
    Cancer Screening
    Cardiology
    Cardiovascular Health
    Care Delivery
    CDC
    Centers For Disease Control
    Cholesterol
    Chronic Disease
    Chronic Illness
    Clinical Education
    Clinical Outreach Education
    Clinical Pharmacists
    Clinical Pharmacy
    Clinician
    Clinician Education
    Clinicians
    CME
    Coaching
    Collaboration
    Colorado
    Colorado ABCD
    Colorado Department Of Public Health And Environment
    Colorectal Cancer
    Communications Skills
    Community-based
    Compliance
    Conference
    Conference Series
    Connecticut
    Consultation
    COPD
    COrE Series
    Cost Savings
    Cultural Competency
    CVS Health
    Data
    Decision Making
    Denver
    Department Of Health
    Dependence
    Depression
    Detailing Aid
    Developmental Delays
    Diabetes
    Director's Letter
    Drug Approval
    Drug Costs
    Drug Regulation
    Drugs
    Drug Safety
    Early Childhood Development
    Education
    Educational Materials
    Efficacy
    Engagement
    Evaluating Evidence
    Evaluation
    Event
    Events
    Evidence
    Evidence-based
    Evidence Based Medicine
    Evidence-based Medicine
    Expert Insight Series
    Expert Panels
    Fall 2016 Training
    Fall 2017 Training
    FDA
    Florida
    Former Trainee
    Formularies
    Gaining Access
    Gatekeeper
    Geronotology
    Getting To Zero
    Guest Blog
    Healthcare
    Healthcare Improvement
    Healthcare Reform
    Health Care System
    Healthcare Transformation
    Health System
    Health Systems
    HealthTeamWorks
    Heart Disease
    Heart Failure
    HEDIS
    HepC
    HIV
    HPV
    Hypertension
    Idaho
    IDIS
    Incontinence
    Interactivity
    Interdisciplinary
    Interview
    Jerry Avorn
    Kaiser Permanente
    Kentucky
    Key Messages
    Keynote Speakers
    Kidney Disease
    LaNet
    LA Net
    Las Vegas
    Learning Center
    Letter
    Lifestyle Management
    Local Response
    Long-term Care
    Los Angeles
    Lung Disease
    Mammography
    Manchester
    Massachusetts
    Massachusetts Department Of Health
    MAT
    Materials Development
    Medical Centers
    Medication
    Medication Assisted Treatment
    Medicine
    Mental Health
    Messaging
    Michigan
    Mississippi
    Morphine Milligram Equivalents
    NACCHO
    Naloxone
    #NaRCAD2014
    #NaRCAD2015
    #NaRCAD2016
    #NaRCAD2017
    #NaRCAD2018
    National AD Service
    Needs Assessment
    Networking
    Nevada
    New Hampshire
    New Mexico
    New York
    North Carolina
    NYDOHMH
    Obesity
    Ohio
    Oklahoma
    On The Road
    Opioid
    Opioid Crisis
    Opioids
    Opioid Use Disorder
    Oregon
    Outreach
    Outreach Education
    Overdose
    Overdose Prevention
    Overprescribing
    Pain Medication
    Partner Network
    Patient Care
    Patients
    PCORI
    PDMP
    PDSA Cycle
    Pediatrics
    Pediatric Screening
    Pennsylvania
    Pertussis
    Pharma
    Pharmaceutial
    Pharmaceutical
    Pharmaceuticals
    Pharmacology
    Pharmacotherapy
    Pharmacy
    Pharmageddon
    Pilot Project
    Policy
    Polypharmacy
    Practice-centered
    Practice Facilitation
    Pregnancy
    Pregnancy-related Depression
    Prenatal Health
    PrEP
    Prescribers
    Prescribing
    Prescribing Guidelines
    Prescription Drug Management
    Prescriptions
    Prevention
    Primary Care
    Primary Care Burnout
    Prisoner Health
    Program Evaluation
    Program Management
    Project PrIDE
    Provider Education
    Providers
    PTSD
    Public Health
    Pulmonology
    Quality Improvement
    RAPID
    Readmission
    Referral
    Registration Open
    Research
    Research Study
    Resources
    Rhode Island
    Role Play
    Rural AD Programs
    Safe Prescribing Guidelines
    San Francisco
    San Francisco Department Of Public Health
    Save The Date
    Scaling Up
    Screening
    Serious Mental Illness
    Sexual Health
    SFDPH
    Smoking Cessation
    Social Marketing
    Social Marketing Skills
    Stakeholders
    Statins
    STDs
    Strategies
    Stroke
    Team Approach
    Technical Assistance
    Technology
    Tennessee
    Texas
    The New Yorker
    Tobacco Treatment
    Total Quality Management
    Training
    Training And Support
    Training Recap
    Training Series
    Transgender
    Transitional Care
    Treatment
    Trends
    VA
    Vaccination
    Vaccinations
    Vermont
    Veterans
    Veterans Affairs
    Veterans Health
    Virginia
    Washington D.C.
    Washington State
    West Virginia
    Workshop
    Zika Virus

    RSS Feed

Picture

​NaRCAD is a program of the Division of Pharmacoepidemiology & Pharmacoeconomics [DoPE], Department of Medicine at Brigham & Women's Hospital and Harvard Medical School, and is funded by  the Agency for Healthcare Research and Quality [AHRQ].

Proudly powered by Weebly